ArticleAntiviral research2014
The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Article in Antiviral research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections.Clinical microbiology reviews · 2019Guideline
- Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024.Antiviral research · 2025Article
- New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.Antiviral research · 2023Article
- A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.Nature communications · 2022Article
- Antivirals Targeting the Neuraminidase.Cold Spring Harbor perspectives in medicine · 2022Review
- Identifying novel amino acid substitutions of hemagglutinin involved in virulence enhancement in H7N9 virus strains.Virology journal · 2021Article
- Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding.Viruses · 2020Article
- A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses.Nature microbiology · 2019Article
- Article
- H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation.Human vaccines & immunotherapeutics · 2018Review
- Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.Antiviral research · 2017Article
- Frequency of influenza H3N2 intra-subtype reassortment: attributes and implications of reassortant spread.BMC biology · 2016Article
- A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action.Reviews in medical virology · 2016Review
- Cooperation between distinct viral variants promotes growth of H3N2 influenza in cell culture.eLife · 2016Article
- Full Genome Characterization of Human Influenza A/H3N2 Isolates from Asian Countries Reveals a Rare Amantadine Resistance-Conferring Mutation and Novel PB1-F2 Polymorphisms.Frontiers in microbiology · 2016Article
- The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.Virology journal · 2015Article
- Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.Journal of virology · 2015Article
- Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.Antimicrobial agents and chemotherapy · 2015Article
- Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013.PloS one · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Propagation of influenza A(H3N2) viruses in MDCK cells has been associated with the emergence of neuraminidase (NA) variants carrying a change at residue 151. In this study, the pyrosequencing assay revealed that ∼90% of A(H3N2) virus isolates analyzed (n=150) contained more than one amino acid variant (D/G/N) at position 151. Susceptibilities of the virus isolates to zanamivir and oseltamivir were assessed using the chemiluminescent and fluorescent NA inhibition (NI) assays. In the chemiluminescent assay, which utilizes NA-Star® substrate, up to 13-fold increase in zanamivir-IC50 was detected for isolates containing a high proportion (>50%) of the G151 NA variant. However, an increase in zanamivir-IC50s was not seen in the fluorescent assay, which uses MUNANA as substrate. To investigate this discrepancy, recombinant NAs (rNAs) were prepared and tested in both NI assays. Regardless of the assay used, the zanamivir-IC50 for the rNA G151 was much greater (>1500-fold) than that for rNA D151 wild-type. However, zanamivir resistance conferred by the G151 substitution was masked in preparations containing the D151 NA which had much greater activity, especially against MUNANA. In conclusion, the presence of NA D151G variants in cell culture-grown viruses interferes with drug susceptibility assessment and therefore measures need to be implemented to prevent their emergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.